Manuscripts
Showing 1549 manuscripts.
Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life
Citation
Lynn McFadyen, Manoli Vourvahis, Luise Rogg, John Moye, Ellen G. Chadwick, Patrick Jean-Philippe, Mark Mirochnick, Kyle Whitson, Sarah Bradford, Edmund V. Capparelli, Brookie M. Best, Marlon Liyanage, Mina Nikanjam. Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Pediatric Infectious Disease Journal. 41: 885-890. PMID: 35980827Journal
Pediatric Infectious Disease Journal
Current strategies to induce selective killing of HIV-1-infected cells.
Citation
Campbell GR, Spector SA. Current strategies to induce selective killing of HIV-1-infected cells.. Journal of Leukocyte Biology. PMID: 35707952Journal
Journal of Leukocyte Biology
Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients
Citation
Helen McIlleron, Jacqueline G Gerhart, Julie B Dumond, Angela D M Kashuba, Paolo Denti, Daniel Gonzalez, Sara N Salerno, Edmund V Capparelli. Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients. Journal of the American College of Clinical Pharmacy. PMID: 35607886Journal
Journal of the American College of Clinical Pharmacy
Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants
Citation
Daniel A. Enquobahrie, Lynda Stranix-Chibanda, Barbra A. Richardson, Anneke C. Hesseling, Sarah Bradford, Linda Aurpibul, Grace Montepiedra, Tapiwa Mbengeranwa, Blandina T. Mmbaga, Amita Gupta, Tapiwa Mbengeranwa, Grace John-Stewart, Gaerolwe Masheto, IMPAACT P1078 TB APPRISE Study Team, Patrick Jean–Phillippe, Nahida Chakhtoura, Gerhard Theron, Adriana Weinberg, Haseena Cassim, Mpho S. Raesi, Elsie Jean, Ashenafi S. Cherkos, Deo Wabwire, Sylvia M. LaCourse, Teacler Nematadzira. Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants. PMID: 36969345Bone and renal health in infants with or without breastmilk exposure to tenofovir-based maternal antiretroviral treatment in the PROMISE randomized trial
Citation
Camlin Tierney, Maxensia Owor, Sufia Dadabhai, Avy Violari, Gerhard Theron, Dhayendre Moodley, Cynthia Mukwasi-Kahari, Kathleen George, John Shepherd, George K. Siberry, Renee Browning, Mary Glenn Fowler, Lynda Stranix-Chibanda, IMPAACT P1084s Study Team, Tichaona Vhembo, Kristin Baltrusaitis. Bone and renal health in infants with or without breastmilk exposure to tenofovir-based maternal antiretroviral treatment in the PROMISE randomized trial. Journal of AIDS. PMID: 37199427Journal
Journal of AIDS
Study
P1084s
Cost-effectiveness of broadly neutralizing antibodies for infant HIV prophylaxis among known HIV-exposed infants in resource-limited settings
Citation
Landon Myer, Milton C. Weinstein, Valériane Leroy, Elizabeth J. McFarland, Kenneth A. Freedberg, Andrea L. Ciaranello, Caitlin M. Dugdale, Ogochukwu Ufio, Christopher Alba, Sallie R. Permar, Lynda Stranix-Chibanda, Coleen K. Cunningham, Genevieve G. Fouda. Cost-effectiveness of broadly neutralizing antibodies for infant HIV prophylaxis among known HIV-exposed infants in resource-limited settings. Journal of International AIDS Society. PMID: 36604316Journal
Journal of International AIDS Society
Comparison of Antiretroviral Therapies in Pregnant Women Living With Human Immunodeficiency Virus and Hepatitis B Virus: A Randomized Controlled Trial
Citation
Neaka Mohtashemi, Hannah Ship, Dingase Dula, Kathy George, Nahida Chaktoura, Karin L Klingman, Mary Glenn Fowler, Marion G Peters, Judith S. Currier, Debika Bhattacharya, Camlin Tierney, Kevin Butler, Flavia Matovu Kiweewa, Dhayendre Moodley, Vani Govender, Tichaona Vhembo. Comparison of Antiretroviral Therapies in Pregnant Women Living With Human Immunodeficiency Virus and Hepatitis B Virus: A Randomized Controlled Trial. Obstetrics and Gynecology. PMID: 37535953Journal
Obstetrics and Gynecology
Study
1077BF, 1077FF
Micronutrients and Nutritional Status among Children living with HIV with and without Severe Acute Malnutrition: IMPAACT P1092
Citation
Renee Browning, John Moye, Tichaona Vhembo, James S. Ngocho, Macpherson Mallewa, Lameck Chinula, Philippa Musoke, Maxensia Owor, IMPAACT P1092 Team, Mutsa Bwakura-Dangarembizi, Lauren Ziemba, Camlin Tierney, Christina Reding, Frederic Bone, Sarah Bradford, Diane Costello. Micronutrients and Nutritional Status among Children living with HIV with and without Severe Acute Malnutrition: IMPAACT P1092. BMC Nutrition. PMID: 37919816Journal
BMC Nutrition
Study
P1092
Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents
Citation
Theodore Ruel, David Burger, Andrew Wiznia, Edward P. Acosta, Lee Fairlie, Rajendra Singh, Lucy Koech, IMPAACT P1093 and ODYSSEY (PENTA 20) Study Teams, Mutsawashe Bwakura-Dangarembizi, Hilda Mujuru, Adeodata R. Kekitiinwa, Cissy M. Kityo, Carmelita Alvero, Hardik Chandasana, Mona Farhad, Mita Thapar, Rohan Hazra, Siobhan Hayes, Ellen Townley, Mark Baker, Ann Buchanan, Diana M Gibb, Pauline Bollen, Anna Turkova, Hylke Waalewijn, Deborah Ford, Angela Colbers. Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents. Clinical Pharmacokinetics. 62: 1445-1459. PMID: 37603217Journal
Clinical Pharmacokinetics
Study
P1093
Impact of Genetic Variants in ABCG2, NR1I2 and UGT1A1 on the Pharmacokinetics of Dolutegravir in Children
Citation
Audrey Chang, Andrew Wiznia, Theodore D. Ruel, Edward P. Acosta, IMPAACT 1093 Team, Stephen A. Spector, Sean S. Brummel. Impact of Genetic Variants in ABCG2, NR1I2 and UGT1A1 on the Pharmacokinetics of Dolutegravir in Children. Journal of Acquired Immune Deficiency Syndromes. 95: doi: 10.1097/QAI.000000000000335. PMID: 38180896Journal
Journal of Acquired Immune Deficiency Syndromes
Study
P1093